Literature DB >> 22148514

Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.

Xiao-Yi Xiao1, Diana K Hunt, Jingye Zhou, Roger B Clark, Nick Dunwoody, Corey Fyfe, Trudy H Grossman, William J O'Brien, Louis Plamondon, Magnus Rönn, Cuixiang Sun, Wu-Yan Zhang, Joyce A Sutcliffe.   

Abstract

This and the accompanying report (DOI: 10.1021/jm201467r ) describe the design, synthesis, and evaluation of a new generation of tetracycline antibacterial agents, 7-fluoro-9-substituted-6-demethyl-6-deoxytetracyclines ("fluorocyclines"), accessible through a recently developed total synthesis approach. These fluorocyclines possess potent antibacterial activities against multidrug resistant (MDR) Gram-positive and Gram-negative pathogens. One of the fluorocyclines, 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline (17j, also known as TP-434, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference , Boston, MA , September 12-15, 2010 , poster F1 - 2157 ), is currently undergoing phase 2 clinical trials in patients with complicated intra-abdominal infections (cIAI).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22148514     DOI: 10.1021/jm201465w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  36 in total

Review 1.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

Review 2.  Eravacycline, a newly approved fluorocycline.

Authors:  Young Ran Lee; Caitlin Elizabeth Burton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-06-07       Impact factor: 3.267

Review 3.  Natural Products in the "Marketplace": Interfacing Synthesis and Biology.

Authors:  Benjamin J Huffman; Ryan A Shenvi
Journal:  J Am Chem Soc       Date:  2019-02-13       Impact factor: 15.419

4.  Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Bo Bo W Maung; Farehin Khan; Ieva Alisauskaite; Melanie Olesky; Joseph Newman; Abdul Mutlib; Xiaoyun Niu; Michael Satlin; Ravi S Singh; Harmut Derendorf; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

5.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

6.  Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli.

Authors:  Trudy H Grossman; William O'Brien; Kathryn O Kerstein; Joyce A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

7.  Fixing the Unfixable: The Art of Optimizing Natural Products for Human Medicine.

Authors:  Audrey E Yñigez-Gutierrez; Brian O Bachmann
Journal:  J Med Chem       Date:  2019-04-26       Impact factor: 7.446

Review 8.  Natural Products as Platforms To Overcome Antibiotic Resistance.

Authors:  Sean E Rossiter; Madison H Fletcher; William M Wuest
Journal:  Chem Rev       Date:  2017-09-27       Impact factor: 60.622

9.  The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques.

Authors:  Trudy H Grossman; Michael S Anderson; Lindsay Drabek; Melanie Gooldy; Henry S Heine; Lisa N Henning; Winston Lin; Joseph V Newman; Rene Nevarez; Kaylyn Siefkas-Patterson; Anne K Radcliff; Joyce A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

10.  Planktonic and Biofilm Activity of Eravacycline against Staphylococci Isolated from Periprosthetic Joint Infections.

Authors:  Georg Zhuchenko; Suzannah Schmidt-Malan; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.